# agilon health, inc.: financial statements, quarterly

AGL · NYSE · CIK 1831097 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/agl.md) · [Financials](/companies/agl/financials.md) · [Filings](/companies/agl/filings.md) · [Insiders](/companies/agl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/agl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,137](/filings/0001628280-24-046286.md) | [1,056 d](/filings/0001628280-26-011655.md) | [1,604](/filings/0001628280-25-022691.md) | [1,483](/filings/0001628280-25-037430.md) | [1,451](/filings/0001628280-25-048839.md) | [1,522 d](/filings/0001628280-26-011655.md) | [1,533](/filings/0001628280-26-031270.md) | [1,395](/filings/0001628280-26-053355.md) | [1,435](/filings/0001628280-25-048839.md) | [1,569 d](/filings/0001628280-26-011655.md) | [1,420](/filings/0001628280-26-031270.md) | [1,495](/filings/0001628280-26-053355.md) |
| Operating income | $m | [(39.3)](/filings/0001628280-24-046286.md) | [(164) d](/filings/0001628280-26-011655.md) | [(7.2)](/filings/0001628280-25-022691.md) | [(43.3)](/filings/0001628280-25-037430.md) | [(134)](/filings/0001628280-25-048839.md) | [(108) d](/filings/0001628280-26-011655.md) | [(22.1)](/filings/0001628280-26-031270.md) | [(116)](/filings/0001628280-26-053355.md) | [(131)](/filings/0001628280-25-048839.md) | [(194) d](/filings/0001628280-26-011655.md) | [4.0](/filings/0001628280-26-031270.md) | [11.8](/filings/0001628280-26-053355.md) |
| Interest expense | $m | [1.7](/filings/0001628280-23-036378.md) | [1.9 d](/filings/0001628280-24-007242.md) | [1.3](/filings/0001628280-24-021088.md) | [1.7](/filings/0001628280-25-037430.md) | [1.6](/filings/0001628280-25-048839.md) | [1.6 d](/filings/0001628280-26-011655.md) | [1.5](/filings/0001628280-26-031270.md) | [1.6](/filings/0001628280-26-053355.md) | [1.8](/filings/0001628280-25-048839.md) | [1.7 d](/filings/0001628280-26-011655.md) | [1.8](/filings/0001628280-26-031270.md) | [1.6](/filings/0001628280-26-053355.md) |
| Income tax | $m | [1.2](/filings/0001628280-24-046286.md) | [0.3 d](/filings/0001628280-26-011655.md) | [(0.1)](/filings/0001628280-25-022691.md) | [0.4](/filings/0001628280-25-037430.md) | [(0.6)](/filings/0001628280-25-048839.md) | [1.8 d](/filings/0001628280-26-011655.md) | [0.2](/filings/0001628280-26-031270.md) | [0.1](/filings/0001628280-26-053355.md) | [(0.3)](/filings/0001628280-25-048839.md) | [1.3 d](/filings/0001628280-26-011655.md) | [0.0](/filings/0001628280-26-031270.md) | [(0.4)](/filings/0001628280-26-053355.md) |
| Net income | $m | [(31.4)](/filings/0001628280-24-046286.md) | [(230) d](/filings/0001628280-26-011655.md) | [(6.1)](/filings/0001628280-25-022691.md) | [(30.7)](/filings/0001628280-25-037430.md) | [(118)](/filings/0001628280-25-048839.md) | [(106) d](/filings/0001628280-26-011655.md) | [12.1](/filings/0001628280-26-031270.md) | [(104)](/filings/0001628280-26-053355.md) | [(110)](/filings/0001628280-25-048839.md) | [(189) d](/filings/0001628280-26-011655.md) | [48.9](/filings/0001628280-26-031270.md) | [18.0](/filings/0001628280-26-053355.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | [0.73](/filings/0001628280-26-031270.md) | [(6.31)](/filings/0001628280-26-053355.md) | not reported | not reported | [2.94](/filings/0001628280-26-031270.md) | [1.04](/filings/0001628280-26-053355.md) |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | [0.73](/filings/0001628280-26-031270.md) | [(6.31)](/filings/0001628280-26-053355.md) | not reported | not reported | [2.95](/filings/0001628280-26-031270.md) | [1.07](/filings/0001628280-26-053355.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [168](/filings/0001628280-23-036378.md) | [108](/filings/0001628280-25-007721.md) | [112](/filings/0001628280-24-021088.md) | [109](/filings/0001628280-24-035179.md) | [148](/filings/0001628280-24-046286.md) | [188](/filings/0001628280-26-011655.md) | [137](/filings/0001628280-25-022691.md) | [171](/filings/0001628280-25-037430.md) | [172](/filings/0001628280-25-048839.md) | [174](/filings/0001628280-26-053355.md) | [140](/filings/0001628280-26-031270.md) | [107](/filings/0001628280-26-053355.md) |
| Current assets | $m | [1,957](/filings/0001628280-23-036378.md) | [1,480](/filings/0001628280-25-007721.md) | [2,037](/filings/0001628280-24-021088.md) | [1,884](/filings/0001628280-24-035179.md) | [1,812](/filings/0001628280-24-046286.md) | [1,458](/filings/0001628280-26-011655.md) | [1,651](/filings/0001628280-25-022691.md) | [1,453](/filings/0001628280-25-037430.md) | [1,338](/filings/0001628280-25-048839.md) | [1,097](/filings/0001628280-26-053355.md) | [1,321](/filings/0001628280-26-031270.md) | [1,419](/filings/0001628280-26-053355.md) |
| Total assets | $m | [2,278](/filings/0001628280-23-036378.md) | [1,741](/filings/0001628280-25-007721.md) | [2,316](/filings/0001628280-24-021088.md) | [2,163](/filings/0001628280-24-035179.md) | [2,091](/filings/0001628280-24-046286.md) | [1,734](/filings/0001628280-26-011655.md) | [1,933](/filings/0001628280-25-022691.md) | [1,713](/filings/0001628280-25-037430.md) | [1,596](/filings/0001628280-25-048839.md) | [1,271](/filings/0001628280-26-053355.md) | [1,505](/filings/0001628280-26-031270.md) | [1,591](/filings/0001628280-26-053355.md) |
| Current liabilities | $m | [1,301](/filings/0001628280-23-036378.md) | [977](/filings/0001628280-25-007721.md) | [1,527](/filings/0001628280-24-021088.md) | [1,387](/filings/0001628280-24-035179.md) | [1,409](/filings/0001628280-24-046286.md) | [1,152](/filings/0001628280-26-011655.md) | [1,375](/filings/0001628280-25-022691.md) | [1,249](/filings/0001628280-25-037430.md) | [1,240](/filings/0001628280-25-048839.md) | [1,076](/filings/0001628280-26-053355.md) | [1,272](/filings/0001628280-26-031270.md) | [1,312](/filings/0001628280-26-053355.md) |
| Total liabilities | $m | [1,406](/filings/0001628280-23-036378.md) | [1,080](/filings/0001628280-25-007721.md) | [1,628](/filings/0001628280-24-021088.md) | [1,487](/filings/0001628280-24-035179.md) | [1,517](/filings/0001628280-24-046286.md) | [1,263](/filings/0001628280-26-011655.md) | [1,433](/filings/0001628280-25-022691.md) | [1,304](/filings/0001628280-25-037430.md) | [1,290](/filings/0001628280-25-048839.md) | [1,145](/filings/0001628280-26-053355.md) | [1,324](/filings/0001628280-26-031270.md) | [1,364](/filings/0001628280-26-053355.md) |
| Long-term debt | $m | [34.8](/filings/0001628280-23-036378.md) | [32.3](/filings/0001628280-25-007721.md) | [29.8](/filings/0001628280-24-021088.md) | [27.4](/filings/0001628280-24-035179.md) | [34.9](/filings/0001628280-24-046286.md) | [34.9](/filings/0001628280-26-011655.md) | [0.0](/filings/0001628280-25-022691.md) | [0.0](/filings/0001628280-25-037430.md) | [0.0](/filings/0001628280-25-048839.md) | [15.8](/filings/0001628280-26-053355.md) | [15.3](/filings/0001628280-26-031270.md) | [15.4](/filings/0001628280-26-053355.md) |
| Current portion of debt | $m | [5.0](/filings/0001628280-23-036378.md) | [6.3](/filings/0001628280-24-035179.md) | [7.5](/filings/0001628280-24-021088.md) | [8.8](/filings/0001628280-24-035179.md) | not reported | [0.0](/filings/0001628280-26-011655.md) | [34.9](/filings/0001628280-25-022691.md) | [34.9](/filings/0001628280-25-037430.md) | [35.0](/filings/0001628280-25-048839.md) | [19.2](/filings/0001628280-26-053355.md) | [14.7](/filings/0001628280-26-031270.md) | [14.9](/filings/0001628280-26-053355.md) |
| Shareholders' equity | $m | [872](/filings/0001628280-23-036378.md) | [662](/filings/0001628280-25-007721.md) | [689](/filings/0001628280-24-021088.md) | [677](/filings/0001628280-24-035179.md) | [575](/filings/0001628280-24-046286.md) | [471](/filings/0001628280-25-007721.md) | [500](/filings/0001628280-26-053355.md) | [409](/filings/0001628280-26-053355.md) | [306](/filings/0001628280-25-048839.md) | [127](/filings/0001628280-26-053355.md) | [181](/filings/0001628280-26-053355.md) | [228](/filings/0001628280-26-053355.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(13.0) d](/filings/0001628280-24-046286.md) | [(61.2) d](/filings/0001628280-26-011655.md) | [(47.8)](/filings/0001628280-25-022691.md) | [(18.7) d](/filings/0001628280-25-037430.md) | [(7.7) d](/filings/0001628280-25-048839.md) | [16.4 d](/filings/0001628280-26-011655.md) | [(32.0)](/filings/0001628280-26-031270.md) | [(35.1) d](/filings/0001628280-26-053355.md) | [(18.2) d](/filings/0001628280-25-048839.md) | [(20.5) d](/filings/0001628280-26-011655.md) | [23.7](/filings/0001628280-26-031270.md) | [(57.3) d](/filings/0001628280-26-053355.md) |
| Capital expenditure | $m | [4.1 d](/filings/0001628280-24-046286.md) | [3.9 d](/filings/0001628280-26-011655.md) | [3.1](/filings/0001628280-25-022691.md) | [3.3 d](/filings/0001628280-25-037430.md) | [3.5 d](/filings/0001628280-25-048839.md) | [3.3 d](/filings/0001628280-26-011655.md) | [3.8](/filings/0001628280-26-031270.md) | [3.3 d](/filings/0001628280-26-053355.md) | [3.2 d](/filings/0001628280-25-048839.md) | [3.0 d](/filings/0001628280-26-011655.md) | [3.1](/filings/0001628280-26-031270.md) | [3.4 d](/filings/0001628280-26-053355.md) |
| Share repurchases | $m | [0.0 d](/filings/0001628280-24-046286.md) | [0.0 d](/filings/0001628280-26-011655.md) | not reported | not reported | [0.0 d](/filings/0001628280-24-046286.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [411](/filings/0001628280-23-036378.md) | [427](/filings/0001628280-24-021088.md) | [410](/filings/0001628280-24-035179.md) | [406](/filings/0001628280-24-046286.md) | [409](/filings/0001628280-25-022691.md) | [411](/filings/0001628280-25-037430.md) | [412](/filings/0001628280-25-048839.md) | [16.5](/filings/0001628280-26-031270.md) | [16.6](/filings/0001628280-26-053355.md) | [414](/filings/0001628280-25-048839.md) | [16.7](/filings/0001628280-26-031270.md) | [17.2](/filings/0001628280-26-053355.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 16,791,210 at 2026-07-30, from the cover of the [10-Q filed 2026-08-05](/filings/0001628280-26-053355.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.